Author + information
- Received March 22, 2018
- Revision received June 13, 2018
- Accepted June 15, 2018
- Published online September 10, 2018.
- David A. Watkins, MD, MPHa,b,c,∗ (, )@davidawatkins@UW,
- Andrea Z. Beaton, MDd,
- Jonathan R. Carapetis, MBBS, PhDe,f,
- Ganesan Karthikeyan, MD, DMg,
- Bongani M. Mayosi, MBChB, DPhilb,h,
- Rosemary Wyber, MBChB, MPHe,i,
- Magdi H. Yacoub, MDj and
- Liesl J. Zühlke, MBChB, MPH, PhDb,c
- aDivision of General Internal Medicine, Department of Medicine, University of Washington, Seattle, Washington
- bDepartment of Medicine, University of Cape Town and Groote Schuur Hospital, Cape Town, South Africa
- cDepartment of Paediatrics, University of Cape Town and Red Cross War Memorial Children’s Hospital, Cape Town, South Africa
- dChildren’s National Health System, Washington, DC
- eTelethon Kids Institute, University of Western Australia, Subiaco, Western Australia, Australia
- fPrincess Margaret Hospital for Children, Perth, Western Australia, Australia
- gDepartment of Cardiology, All India Institute of Medical Sciences, New Delhi, India
- hThe Deans Suite, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa
- iOffice of the Chief Scientist, The George Institute for Global Health, UNSW Sydney, Camperdown, New South Wales, Australia
- jAswan Heart Centre, Aswan, Egypt
- ↵∗Address for correspondence:
Dr. David A. Watkins, Division of General Internal Medicine, Department of Medicine, University of Washington, 325 9th Avenue, Box 359780, Seattle, Washington 98104.
Rheumatic heart disease (RHD) is a preventable heart condition that remains endemic among vulnerable groups in many countries. After a period of relative neglect, there has been a resurging interest in RHD worldwide over the past decade. In this Scientific Expert Panel, the authors summarize recent advances in the science of RHD and sketch out priorities for current action and future research. Key questions for laboratory research into disease pathogenesis and epidemiological research on the burden of disease are identified. The authors present a variety of pressing clinical research questions on optimal RHD prevention and advanced care. In addition, they propose a policy and implementation research agenda that can help translate current evidence into tangible action. The authors maintain that, despite knowledge gaps, there is sufficient evidence for national and global action on RHD, and they argue that RHD is a model for strengthening health systems to address other cardiovascular diseases in limited-resource countries.
Dr. Watkins has received support from the RHD Action grant from Medtronic Foundation outside of the submitted work. Dr. Carapetis has received funding from Novartis Institutes for Biomedical Research. Dr. Wyber has received funding from the Postgraduate Scholarship from the National Health and Medical Research Council (NHMRC), Australia, and from the Telethon Kids Institute. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.
- Received March 22, 2018.
- Revision received June 13, 2018.
- Accepted June 15, 2018.
- 2018 American College of Cardiology Foundation
This article requires a subscription or purchase to view the full text. If you are a subscriber or member, click Login or the Subscribe link (top menu above) to access this article.